out of the labyrinth

GST’s attack on pharma’s weakest link: distribution

Age: 30. Nature: Unpredictable. Size: 80,000+. Status: Diminished by 25%, in just 15 months. Prognosis: Pharma distribution is under the scalpel

21/09/18

Ruhi Kandhari

Since GST was implemented, India’s labyrinthine drug distribution network has begun to change rapidly

The majority of large carry and forwarding agents and small distributors have lost business

The supply chain is now simplifying, with e-pharmacies and private equities like Everstone Capital developing their own supply chains

As drug manufacturers get closer to patients, drugs are getting more accessible. But can they get more affordable?

Want to read a free 200 word summary?

At least once a month, Bhavik Kumar, founder and CEO of Medibox, gets a panicked call. The callers are worried Indian medicine distributors, desperate to either shut down or get acquired. As the head of Medibox, a digital platform for e-marketing, e-procurement and e-distribution of medicines and healthcare products, Kumar is in a unique position….

To access this post, you must purchase Monthly Recurring, Quarterly or Weekly Product.

Read the full story.
Subscribe now.

Why subscribe? Let us explain.

Already Registered?